Patrys Secures 50% Revenue Share in IP Commercialisation
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Patrys Limited has announced a binding agreement with Yale University for a revenue-sharing arrangement regarding the deoxymab intellectual property portfolio. This transaction aims to reduce Patrys' future capital requirements while allowing continued development of the deoxymab platform through university-supported initiatives. The agreement is seen as a strategic milestone that preserves shareholder exposure to potential future commercial success of the deoxymab portfolio.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Patrys
- Patrys advances RLS-2202 toward Phase 1 Clinical Trial
- Appendix 4C - Quarterly - 31 March 2026
- $3.2 million Placement to Advance Clinical Trials
- Investor Presentation - Broker Meets Biotech
- RLS-2201 Manufacturing and Regulatory Pathway Initiated
Later from Patrys
- Appendix 4C - Quarterly - 30 June 2026
- Investor Presentation - TechKnow Invest Roadshow
- Ethics Approval Secured for Phase 1A Clinical Trial
- Appendix 4E - Preliminary Final Report
- PAB Establishes Clinical Advisory Committee
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys